Sage Therapeutics, Inc. - Common Stock (SAGE)
Frequently Asked Questions About Sage Therapeutics, Inc. - Common Stock (SAGE)
How does Sage Therapeutics approach regulatory compliance?
Sage Therapeutics prioritizes regulatory compliance by following strict guidelines set forth by authorities such as the FDA. The company ensures that its clinical trials, product development, and marketing practices align with current regulations and safety standards.
How does Sage Therapeutics contribute to the community?
Sage Therapeutics is actively engaged in the community through various initiatives, including patient advocacy, educational programs, and collaborations with healthcare providers. The company aims to raise awareness about brain health disorders and support research efforts.
How is Sage Therapeutics funded?
Sage Therapeutics is funded through a combination of public offerings, private investments, collaborations with other pharmaceutical companies, and grants. This funding supports their research and development and allows them to advance their clinical programs.
What are Sage Therapeutics' long-term goals?
Sage Therapeutics’ long-term goals include expanding its portfolio of innovative therapies for brain health disorders, advancing its research capabilities, and ultimately improving treatment options for patients struggling with neurological conditions.
What are some key products developed by Sage Therapeutics?
One of Sage Therapeutics' most notable products is zulresso (brexanolone), which is the first FDA-approved treatment specifically for postpartum depression. The company is also working on other therapeutic candidates aimed at various neurological conditions.
What are some upcoming milestones for Sage Therapeutics?
Sage Therapeutics has several upcoming milestones, including the results of ongoing clinical trials, potential new drug applications, and updates related to partnerships and collaborations. These milestones are important indicators of the company’s growth and the advancement of its product pipeline.
What clinical trials is Sage Therapeutics currently conducting?
Sage Therapeutics is currently conducting various clinical trials targeting conditions such as major depressive disorder, epilepsy, and other neuropsychiatric disorders. These trials are essential for determining the safety and efficacy of their investigational therapies.
What does Sage Therapeutics, Inc. do?
Sage Therapeutics, Inc. is a biopharmaceutical company that focuses on developing innovative therapies for the treatment of brain health disorders. The company's research primarily emphasizes conditions like depression, epilepsy, and other neuropsychiatric disorders, aiming to create solutions that fundamentally improve the lives of patients.
What is the company's approach to drug development?
Sage Therapeutics employs a science-driven approach to drug development that combines extensive research with robust clinical trials. The company aims to conduct rigorous studies to ensure that its products are not only effective but also safe for patients.
What is the management structure of Sage Therapeutics?
Sage Therapeutics is led by a team of experienced executives with backgrounds in pharmaceuticals, research, and finance. The management structure includes a Board of Directors, CEO, and various department heads overseeing key functions such as research, clinical development, and operations.
What is the mission of Sage Therapeutics?
Sage Therapeutics' mission is to develop and deliver innovative medicines that can transform the treatment landscape for brain health disorders. The company is committed to addressing unmet needs in the therapeutic realm and improving patient outcomes.
What is the significance of zulresso?
Zulresso (brexanolone) is significant because it represents a breakthrough in the treatment of postpartum depression, a condition that affects many new mothers and can have serious implications for both the mother and child. Its approval marked a major advancement in the options available for treating this condition.
What is the stock symbol for Sage Therapeutics, Inc.?
Sage Therapeutics is publicly traded on the NASDAQ stock exchange under the ticker symbol 'SAGE'. This allows investors to buy and sell shares of the company, providing access to its financial performance and growth potential.
What partnerships does Sage Therapeutics have?
Sage Therapeutics has established partnerships with several organizations and academic institutions to advance its research and development efforts. These collaborations help to leverage additional expertise and resources, enhancing the company's capabilities.
When was Sage Therapeutics founded?
Sage Therapeutics was founded in 2010. Since its inception, the company has dedicated itself to advancing treatments for disorders of the nervous system, utilizing cutting-edge research and drug development methodologies.
Where is Sage Therapeutics headquartered?
Sage Therapeutics is headquartered in Cambridge, Massachusetts. This location is at the heart of a vibrant scientific community and biotech industry, providing the company with access to top talent and resources.
Who are Sage Therapeutics' key competitors?
Sage Therapeutics faces competition from other biopharmaceutical companies specializing in neuroscience and mental health, such as Eli Lilly, Bristol-Myers Squibb, and Axovant Gene Therapies. The field is competitive due to the high demand for effective treatments.
Who are the founders of Sage Therapeutics?
Sage Therapeutics was co-founded by Dr. Jeffrey J. N. D. F. C. G. G. K. R. Joshi and is supported by a team of experienced professionals from scientific and pharmaceutical backgrounds.
Why is Sage Therapeutics focused on brain health?
Sage Therapeutics believes that the brain is one of the most critical and complex organs in the human body, and disorders affecting it can severely impact patients' quality of life. By addressing brain health, the company aims to develop targeted therapies that can lead to transformative improvements in treatment efficacy.
What is the current price of Sage Therapeutics, Inc. - Common Stock?
The current price of Sage Therapeutics, Inc. - Common Stock is 7.770
When was Sage Therapeutics, Inc. - Common Stock last traded?
The last trade of Sage Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Sage Therapeutics, Inc. - Common Stock?
The market capitalization of Sage Therapeutics, Inc. - Common Stock is 464.35M
How many shares of Sage Therapeutics, Inc. - Common Stock are outstanding?
Sage Therapeutics, Inc. - Common Stock has 59.76M shares outstanding.